Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy

BACKGROUND: Anlotinib, an oral small molecule tyrosine kinase inhibitor targeting VEGFR 1/2/3, FGFR 1-4, PDGFR a/β, and c-kit, had demonstrated prolonged progression-free survival (PFS) in refractory metastatic colorectal cancer (mCRC). This multicenter, single-arm, phase II, exploratory study was c...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yue, Xiao, Qian, He, Jinjie, Hu, Hanguang, Du, Jinlin, Zhu, Yuping, Chen, Jiaqi, Liu, Zhuo, Wang, Jianping, Sun, Lifeng, Xu, Dong, Li, Jun, Liao, Xiujun, Wang, Jianwei, Cai, Yibo, Cai, Cheng, Jin, Zhekang, Wang, Liuhong, Yuan, Ying, Ding, Kefeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071922/
https://www.ncbi.nlm.nih.gov/pubmed/35513832
http://dx.doi.org/10.1186/s12916-022-02357-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071922/
https://www.ncbi.nlm.nih.gov/pubmed/35513832
http://dx.doi.org/10.1186/s12916-022-02357-6

Ejemplares similares